Another Feather In Cap For Orchard’s Gene Therapy Product Following UK PIM designation
Executive Summary
Orchard Therapeutics’ gene therapy product for treating the rare, so called “bubble baby” disease has been granted a “promising innovative medicine” designation under the UK’s early access to medicine scheme. The product already has orphan drug, breakthrough therapy and rare pediatric disease designations in the US.